General Announcement::Glenmark Pharmaceuticals receives tentative ANDA approval for Abiraterone Acetate Tablets USP

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
23-Jan-2019 13:29:50
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals receives tentative ANDA approval for Abiraterone Acetate Tablets USP
Announcement Reference
SG190123OTHRPON0
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
23/01/2019 10:57:00
Description (Please provide a detailed description of the event in the box below)
Sub: Glenmark Pharmaceuticals receives tentative ANDA approval for Abiraterone Acetate Tablets USP, 250 mg

With reference to the subject mentioned above, kindly find attached media release which is self explanatory.

Request you to kindly take the same on record.

Attachments

SGX_PR_23012019_signed.pdf
Total size =255K